Overview

Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)

Status:
Recruiting
Trial end date:
2021-11-30
Target enrollment:
Participant gender:
Summary
A multicenter phase II non-randomised trial assessing the efficacy of domatinostat (4SC-202) plus avelumab in patients with GI cancer
Phase:
Phase 2
Details
Lead Sponsor:
Royal Marsden NHS Foundation Trust
Collaborators:
4SC AG
Merck KGaA, Darmstadt, Germany
Treatments:
Avelumab